Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Veziris

Showing results (21-30 of 114) with videos related to

Pageof 12
Sort By:
Antimicrobial Agents and Chemotherapy|September 25, 2003
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivoNicolas Veziris, Chantal Truffot-Pernot, Alexandra Aubry, et al.
Journal of Clinical Microbiology|October 6, 2006
Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistanceFlorence Brossier, Nicolas Veziris, Chantal Truffot-Pernot, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2009
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosisMurad Ibrahim, Chantal Truffot-Pernot, Koen Andries, et al.
BMC Infectious Diseases|January 14, 2014
Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysisVanina Meyssonnier, Thuy Van Bui, Nicolas Veziris, et al.
The Journal of Antimicrobial Chemotherapy|September 9, 2016
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic testsChristine Bernard, Alexandra Aubry, Aurélie Chauffour, et al.
Plos Neglected Tropical Diseases|September 1, 2020
Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 dosesAurélie Chauffour, Jérôme Robert, Nicolas Veziris, et al.
BMC Infectious Diseases|November 18, 2021
Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide studyNicolas Veziris, Claire Andréjak, Stéphane Bouée, et al.
Plos Neglected Tropical Diseases|November 27, 2023
Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosyAurélie Chauffour, Nacer Lounis, Koen Andries, et al.
Journal of Clinical Microbiology|July 10, 2015
Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (-15C→T)Florence Brossier, Christophe Sola, Christine Bernard, et al.
Journal of Clinical Microbiology|October 3, 2014
Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulareAurélie Renvoisé, Christine Bernard, Nicolas Veziris, et al.
Pageof 12

Showing results (21-30 of 114) with videos related to

Sort By:
Pageof 12
Antimicrobial Agents and Chemotherapy|September 25, 2003
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivoNicolas Veziris, Chantal Truffot-Pernot, Alexandra Aubry, et al.
Journal of Clinical Microbiology|October 6, 2006
Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistanceFlorence Brossier, Nicolas Veziris, Chantal Truffot-Pernot, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2009
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosisMurad Ibrahim, Chantal Truffot-Pernot, Koen Andries, et al.
BMC Infectious Diseases|January 14, 2014
Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysisVanina Meyssonnier, Thuy Van Bui, Nicolas Veziris, et al.
The Journal of Antimicrobial Chemotherapy|September 9, 2016
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic testsChristine Bernard, Alexandra Aubry, Aurélie Chauffour, et al.
Plos Neglected Tropical Diseases|September 1, 2020
Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 dosesAurélie Chauffour, Jérôme Robert, Nicolas Veziris, et al.
BMC Infectious Diseases|November 18, 2021
Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide studyNicolas Veziris, Claire Andréjak, Stéphane Bouée, et al.
Plos Neglected Tropical Diseases|November 27, 2023
Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosyAurélie Chauffour, Nacer Lounis, Koen Andries, et al.
Journal of Clinical Microbiology|July 10, 2015
Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (-15C→T)Florence Brossier, Christophe Sola, Christine Bernard, et al.
Journal of Clinical Microbiology|October 3, 2014
Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulareAurélie Renvoisé, Christine Bernard, Nicolas Veziris, et al.
Pageof 12